Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Recent move in Guardant Health stock
Guardant Health (GH) has drawn fresh attention after a recent share move, with the stock up around 25% over the past week and 33% over the past month on available return figures.
See our latest analysis for Guardant Health.
That sharp 25.3% 7 day share price return and 32.8% 30 day share price return come on top of a 16.9% year to date share price gain. The 1 year total shareholder return is 213% and the 3 year total shareholder return is very large at over 3x.
If Guardant Health’s recent surge has you rethinking your exposure to healthcare AI, it could be a good moment to broaden your watchlist with 34 healthcare AI stocks
With Guardant Health now valued at around US$15.6b on US$1.08b of revenue and a reported net loss of US$433.2m, you have to ask: is this surge creating a fresh entry point, or is the market already pricing in future growth?
Most Popular Narrative: 7.3% Undervalued
Guardant Health’s most followed narrative puts fair value at $128.33 per share, slightly above the last close of $118.95, and frames that gap around ambitious growth and margin assumptions.
Substantial regulatory, reimbursement, and clinical validation milestones (including Shield’s breakthrough device status, NCCN guideline inclusion, and ongoing pilot studies) are paving the way for further guideline adoption, expanded payer coverage, and commercial inflections in Shield/MCED and Reveal volumes, significantly increasing future revenue and earnings visibility.
Curious what kind of revenue ramp, margin lift, and valuation multiple this narrative leans on. The key ingredients are bold, tightly linked, and very specific.
At the core of this narrative, analysts are tying together high double digit revenue expectations, a swing from current losses toward positive margins over time, and a discount rate of 6.98% to bridge future cash generation back to a fair value of $128.33. That mix creates a valuation that sits modestly above the market price, but still leaves the final judgment up to how comfortable you are with those underlying assumptions.
Result: Fair Value of $128.33 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this story can change quickly if heavy ongoing cash burn or slower than expected payer adoption for Shield and other tests undercuts those bullish margin and revenue assumptions.
